Form 8-K - Current report:
SEC Accession No. 0001213900-25-062099
Filing Date
2025-07-08
Accepted
2025-07-08 17:00:27
Documents
13
Period of Report
2025-07-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248335-8k_citius.htm   iXBRL 8-K 24145
2 PRESS RELEASE, DATED JULY 8, 2025 ea024833501ex99-1_citius.htm EX-99.1 7817
  Complete submission text file 0001213900-25-062099.txt   200901

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ctxr-20250707.xsd EX-101.SCH 3026
4 XBRL LABEL FILE ctxr-20250707_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ctxr-20250707_pre.xml EX-101.PRE 22366
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0248335-8k_citius_htm.xml XML 3683
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 251111567
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)